Fenwick Represents Merck Global Health Innovation Fund in N-Power Medicine’s Series B Funding

Fenwick represented Merck Global Health Innovation Fund, the corporate venture capital arm of Merck, in its investment in N-Power Medicine’s Series B funding. The round, which brought N-Power Medicine’s total funding to date to $72 million, was led by Merck Global Health Innovation Fund, with participation from a US-based healthcare focused investor.

N-Power Medicine is a clinical research and drug development platform company that aims to dramatically boost clinical trial participation to accelerate oncology drug development and will use the funds to support the expansion of its network of oncology clinics and biopharmaceutical company collaborations. More information is available in N-Power's announcement.

The Fenwick transaction team was led by corporate partners Ian Goldstein and Ryan McRobert and included associates Aaron Ginsburg, Jefferson Lin, and Teresa Anselmo-Thai.